NCT06785493Completed
The Clinical Efficacy and Influence Factors of Individualized Treatment of Ustekinumab in Crohn's Disease
A Retrospective Analysis on the Clinical Efficacy and Influence Factors of Individualized Treatment of Ustekinumab in Patients With Crohn's Disease
Source: ClinicalTrials.gov · Last updated 21 Jan 2025
Brief summary (registry, in English)
The loss of response rate of ustekinumab(UST) is high, and the specific mechanism has not yet been elucidated. Our study aimed to retrospectively analyze the clinical efficacy and influence factors of individualized treatment of ustekinumab (UST) in patients with Crohn's disease (CD).
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 122 (actual)
- First submitted
- 13 Jan 2025
- Start date
- 1 Jul 2020
- Primary completion date
- 31 Jul 2024
- Lead sponsor
- Second Affiliated Hospital of Wenzhou Medical University
- Diseases
- Crohn's disease
- NCT number
- NCT06785493
What you commit to
- Study type: Observational
- Participants enrolled: 122
- From 1 Jul 2020 to the primary completion date, 31 Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Combination therapy with hormones, immunosuppressants, small molecule drugs, or other biological agents
Other illness
- Combined with other autoimmune diseases (such as systemic lupus erythematosus, Sjogren's syndrome, etc.), malignant tumors, or severe cardiovascular and cerebrovascular diseases
- Merge active tuberculosis or severe infection
Other
- Liver and kidney dysfunction
- Pregnancy or lactation period
- Clinical data missing ≥ 30% or lost to follow-up during the follow-up period.
Who the study is looking for
- Diagnosed with moderate to severe Crohn's disease
- Receiving treatment with ustekinumab
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Second Affiliated Hospital of Wenzhou Medical University Coordinator of this site? Confirm its status | Wenzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.